Cargando…
Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone A...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244378/ https://www.ncbi.nlm.nih.gov/pubmed/34223253 http://dx.doi.org/10.1016/j.xfre.2020.09.010 |
_version_ | 1783715921780539392 |
---|---|
author | Robins, Jared C. Khair, Andrew F. Widra, Eric A. Alper, Michael M. Nelson, Winnie W. Foster, Eric D. Sinha, Anshul Ando, Masakazu Heiser, Patrick W. Daftary, Gaurang S. |
author_facet | Robins, Jared C. Khair, Andrew F. Widra, Eric A. Alper, Michael M. Nelson, Winnie W. Foster, Eric D. Sinha, Anshul Ando, Masakazu Heiser, Patrick W. Daftary, Gaurang S. |
author_sort | Robins, Jared C. |
collection | PubMed |
description | OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial. DESIGN: Cost minimization analysis of trial results. SETTING: Thirty-one fertility centers. PATIENT(S): Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL. INTERVENTION(S): Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S): Mean cost of achieving live birth after first transfer (fresh or frozen). RESULT(S): First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH. CONCLUSION(S): Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER: NCT02554279. |
format | Online Article Text |
id | pubmed-8244378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82443782021-07-02 Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial Robins, Jared C. Khair, Andrew F. Widra, Eric A. Alper, Michael M. Nelson, Winnie W. Foster, Eric D. Sinha, Anshul Ando, Masakazu Heiser, Patrick W. Daftary, Gaurang S. F S Rep Original Article OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial. DESIGN: Cost minimization analysis of trial results. SETTING: Thirty-one fertility centers. PATIENT(S): Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL. INTERVENTION(S): Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S): Mean cost of achieving live birth after first transfer (fresh or frozen). RESULT(S): First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH. CONCLUSION(S): Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER: NCT02554279. Elsevier 2020-11-10 /pmc/articles/PMC8244378/ /pubmed/34223253 http://dx.doi.org/10.1016/j.xfre.2020.09.010 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Robins, Jared C. Khair, Andrew F. Widra, Eric A. Alper, Michael M. Nelson, Winnie W. Foster, Eric D. Sinha, Anshul Ando, Masakazu Heiser, Patrick W. Daftary, Gaurang S. Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title | Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title_full | Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title_fullStr | Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title_full_unstemmed | Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title_short | Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial |
title_sort | economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the menopur in gonadotropin-releasing hormone antagonist single embryo transfer–high responder (megaset-hr) trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244378/ https://www.ncbi.nlm.nih.gov/pubmed/34223253 http://dx.doi.org/10.1016/j.xfre.2020.09.010 |
work_keys_str_mv | AT robinsjaredc economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT khairandrewf economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT widraerica economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT alpermichaelm economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT nelsonwinniew economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT fosterericd economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT sinhaanshul economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT andomasakazu economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT heiserpatrickw economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial AT daftarygaurangs economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial |